HC Wainwright Expects Higher Earnings for BioLife Solutions

BioLife Solutions, Inc. (NASDAQ:BLFS) – Analysts at HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for shares of BioLife Solutions in a research note issued to investors on Thursday, July 23rd. HC Wainwright analyst Y. Chen now anticipates that the medical equipment provider will post earnings of ($0.01) per share for the quarter, up from their prior forecast of ($0.02). HC Wainwright has a “Neutral” rating and a $31.00 price target on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for BioLife Solutions’ FY2026 earnings at $0.03 EPS.

BLFS has been the topic of several other reports. Jefferies Financial Group downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating and lifted their price objective for the company from $30.00 to $31.00 in a research report on Thursday, July 23rd. Craig Hallum cut shares of BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 target price for the company. in a research report on Wednesday, July 22nd. Maxim Group lowered shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. TD Cowen lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating and dropped their price target for the company from $33.00 to $31.00 in a research note on Wednesday, July 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $31.38.

BioLife Solutions Stock Performance

Shares of BLFS opened at $31.98 on Monday. BioLife Solutions has a 1 year low of $17.86 and a 1 year high of $33.14. The company has a market cap of $1.56 billion, a price-to-earnings ratio of -399.70 and a beta of 1.94. The firm has a fifty day moving average of $27.27 and a 200-day moving average of $23.60.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The firm had revenue of $27.50 million during the quarter, compared to the consensus estimate of $25.66 million. BioLife Solutions had a positive return on equity of 1.81% and a negative net margin of 2.80%.

Insider Buying and Selling

In other BioLife Solutions news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $23.70, for a total transaction of $15,405,000.00. Following the sale, the insider directly owned 4,757,165 shares in the company, valued at approximately $112,744,810.50. The trade was a 12.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders have sold 1,200,000 shares of company stock worth $28,125,000. 2.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its position in BioLife Solutions by 2.7% during the second quarter. The Manufacturers Life Insurance Company now owns 20,764 shares of the medical equipment provider’s stock valued at $447,000 after acquiring an additional 555 shares in the last quarter. Isthmus Partners LLC grew its position in BioLife Solutions by 0.5% in the fourth quarter. Isthmus Partners LLC now owns 138,393 shares of the medical equipment provider’s stock worth $3,346,000 after acquiring an additional 622 shares in the last quarter. Thrivent Financial for Lutherans grew its position in BioLife Solutions by 2.6% in the second quarter. Thrivent Financial for Lutherans now owns 27,278 shares of the medical equipment provider’s stock worth $588,000 after acquiring an additional 702 shares in the last quarter. Quarry LP increased its stake in shares of BioLife Solutions by 50.9% during the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 713 shares during the last quarter. Finally, Millennium Management LLC increased its stake in shares of BioLife Solutions by 2.9% during the 3rd quarter. Millennium Management LLC now owns 27,698 shares of the medical equipment provider’s stock worth $707,000 after purchasing an additional 783 shares during the last quarter. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.